<DOC>
	<DOCNO>NCT01896830</DOCNO>
	<brief_summary>The aim study evaluate candidate C. difficile Toxoid Vaccine Japanese population . Primary objective : - To describe safety profile subject receive least 1 injection - To describe immunogenicity toxin A toxin B subject serum sample obtain Days 0 , 14 , 30 , 60 .</brief_summary>
	<brief_title>Study Candidate Clostridium Difficile Toxoid Vaccine Healthy Adult Subjects Aged 40 75 Years Japan</brief_title>
	<detailed_description>Participants randomly assign receive vaccine placebo select schedule . Safety parameter , solicit injection site systemic reaction collect 6 day injection ; unsolicited adverse event include serious adverse event collect Day 60 post-vaccination .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult subject age 40 75 year day inclusion Informed consent form sign date Able attend schedule visit comply trial procedure . Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior first vaccination least 4 week last vaccination ) Participation 4 week precede first trial vaccination plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week precede first trial vaccination , except influenza ( seasonal pandemic ) pneumococcal vaccine . Planned receipt vaccine study vaccination 4 week follow last trial vaccination , except influenza ( seasonal pandemic ) pneumococcal vaccine Previous vaccination C. difficile either trial vaccine another vaccine , monoclonal antibody Selfreported current prior Clostridium difficile infection ( CDI ) episode Receipt blood bloodderived product past 3 month , might interfere assessment immune response Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Selfreported seropositivity human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C Known systemic hypersensitivity vaccine component ( include aluminum hydroxide , sodium citrate , sucrose , formaldehyde , sodium chloride ) , history lifethreatening reaction vaccine contain substance Known medical history concomitant disease thrombocytopenia Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction might interfere ability comply trial procedure Chronic illness , opinion investigator , stage might interfere trial conduct completion Subjects history intestinal diverticular bleed Subjects surgery within past three month GastroIntestinal malignancy Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥ 37.5°C ) . A prospective subject include study condition resolve febrile event subside Identified Investigator employee Investigator study center direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study Subject concomitant disease , accord investigator's/subinvestigator 's judgment , would adversely affect safety subject study , e.g. , cardiovascular disease , renal disease , hepatic disease , hematologic disease , and/or growth impairment Subject past history convulsion Subject ineligible participation study accord investigator's/subinvestigator 's judgment .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Clostridium difficile infection</keyword>
	<keyword>Clostridium difficile Toxoid Vaccine</keyword>
</DOC>